- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses the Importance of New CKD Section in ADA Guidelines
Robert Gabbay, MD, PhD, of the American Diabetes Association, explains why a section on chronic kidney disease management was added to the ADA's 2022 standard of care guidelines.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), explains why a section on chronic kidney disease (CKD) management was added to the ADA's 2022 standard of care guidelines.
Transcript:
What evidence led to the addition of Section 11 in the ADA’s 2022 guidelines?
Gabbay: [A couple] of the things that became clear based on some of the recent studies and new treatments that are available are a couple of things. One, we know that chronic kidney disease continues to be a huge issue and it's under-diagnosed and under-treated. And second, we now have new treatments that can really lower the risk of chronic kidney disease, and particularly the progression. So, we called out all of that information by making chronic kidney disease a separate section [of the guidelines] to emphasize the importance of it.
Empagliflozin Reduces HF Risk After AMI in Patients With or Without Diabetes, CKD
October 30th 2025Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.
Read More
